ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy.

In this interview, Judith S. Hochman MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report.

Related References:

  1. Maron et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407.
  2. Anthopolos et al. ISCHEMIA-EXTEND studies: Rationale and design. American Heart Journal. 2022;254:228-233.
  3. Bangalore et al. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2020;142:841-857.

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Atherosclerotic Disease (CAD/PAD), Interventions and Coronary Artery Disease, Acute Coronary Syndromes, Noninvasive Imaging, Pulmonary Hypertension and Venous Thromboembolism, Stable Ischemic Heart Disease

Keywords: ACCELLite, AHA Annual Scientific Sessions, Cardiac Surgical Procedures, AHA22, Cardiology Interventions, Coronary Artery Disease, Ischemia

< Back to Listings